748 related articles for article (PubMed ID: 34301762)
1. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
2. Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.
Zheng H; Zheng WJ; Wang ZG; Tao YP; Huang ZP; Yang L; Ouyang L; Duan ZQ; Zhang YN; Chen BN; Xiang DM; Jin G; Fang L; Zhou F; Liang B
Front Immunol; 2022; 13():845193. PubMed ID: 35154166
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
4. ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression.
You Y; Wen D; Zeng L; Lu J; Xiao X; Chen Y; Song H; Liu Z
Int J Biol Sci; 2022; 18(13):5001-5018. PubMed ID: 35982895
[TBL] [Abstract][Full Text] [Related]
5. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
7. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract][Full Text] [Related]
8. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
[TBL] [Abstract][Full Text] [Related]
10. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
12. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
Lomphithak T; Akara-Amornthum P; Murakami K; Hashimoto M; Usubuchi H; Iwabuchi E; Unno M; Cai Z; Sasano H; Jitkaew S
Sci Rep; 2021 Jun; 11(1):11743. PubMed ID: 34083572
[TBL] [Abstract][Full Text] [Related]
13. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment.
Li N; Kang Y; Wang L; Huff S; Tang R; Hui H; Agrawal K; Gonzalez GM; Wang Y; Patel SP; Rana TM
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20159-20170. PubMed ID: 32747553
[TBL] [Abstract][Full Text] [Related]
14. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
[TBL] [Abstract][Full Text] [Related]
15. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
Fontugne J; Augustin J; Pujals A; Compagnon P; Rousseau B; Luciani A; Tournigand C; Cherqui D; Azoulay D; Pawlotsky JM; Calderaro J
Oncotarget; 2017 Apr; 8(15):24644-24651. PubMed ID: 28445951
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
[TBL] [Abstract][Full Text] [Related]
19. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
[TBL] [Abstract][Full Text] [Related]
20. m
Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
